Healthcare provider profile · identity verified

Douglas F. Epperson, MD

Internal Medicine · OAKLAND, CA · NPI 1689752453

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	395	148
Amlodipine Besylate	Amlodipine Besylate	213	80
Lisinopril	Lisinopril	162	55
Levothyroxine Sodium	Levothyroxine Sodium	152	51
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	138	39
Famotidine	Famotidine	131	44
Hydrochlorothiazide	Hydrochlorothiazide	130	51
Losartan Potassium	Losartan Potassium	117	44
Tamsulosin Hcl	Tamsulosin Hcl	115	41
Gabapentin	Gabapentin	109	37
Lorazepam	Lorazepam	104	30
Metformin Hcl Er	Metformin Hcl	71	22
Acyclovir	Acyclovir	68	19
Ibuprofen	Ibuprofen	68	28
Metoprolol Tartrate	Metoprolol Tartrate	68	22
Atenolol	Atenolol	66	25
Fluticasone Propionate	Fluticasone Propionate	60	24
Albuterol Sulfate Hfa	Albuterol Sulfate	57	37
Lovastatin	Lovastatin	57	20
Alendronate Sodium	Alendronate Sodium	55	24
Citalopram Hbr	Citalopram Hydrobromide	55	15
Omeprazole	Omeprazole	54	19
Tramadol Hcl	Tramadol Hcl	54	13
Allopurinol	Allopurinol	49	17
Pantoprazole Sodium	Pantoprazole Sodium	47	18
Rosuvastatin Calcium	Rosuvastatin Calcium	47	22
Metoprolol Succinate	Metoprolol Succinate	46	16
Tizanidine Hcl	Tizanidine Hcl	46	17
Azelastine Hcl	Azelastine Hcl	45	21
Simvastatin	Simvastatin	44	18
Trazodone Hcl	Trazodone Hcl	43	23
Duloxetine Hcl	Duloxetine Hcl	40	18
Sertraline Hcl	Sertraline Hcl	39	14
Zolpidem Tartrate	Zolpidem Tartrate	38	13
Meloxicam	Meloxicam	37	17
Alvesco	Ciclesonide	35	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	17
Temazepam	Temazepam	33	suppressed
Metformin Hcl	Metformin Hcl	32	13
Triamcinolone Acetonide	Triamcinolone Acetonide	31	14
Finasteride	Finasteride	30	11
Potassium Chloride	Potassium Chloride	30	suppressed
Breyna	Budesonide/Formoterol Fumarate	29	14
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Furosemide	Furosemide	29	11
Baclofen	Baclofen	28	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	27	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	25	13
Chlorthalidone	Chlorthalidone	24	suppressed
Terazosin Hcl	Terazosin Hcl	24	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	23	23
Bupropion Hcl Sr	Bupropion Hcl	23	suppressed
Glipizide	Glipizide	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Mirtazapine	Mirtazapine	23	12
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Oxycodone Hcl	Oxycodone Hcl	21	suppressed
Ozempic	Semaglutide	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Cefadroxil	Cefadroxil	20	18
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	16	suppressed
Eliquis	Apixaban	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Amoxicillin	Amoxicillin	15	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	12
Pregabalin	Pregabalin	15	suppressed
Trospium Chloride	Trospium Chloride	15	suppressed
Colchicine	Colchicine	14	suppressed
Diazepam	Diazepam	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Fluocinonide	Fluocinonide	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Oxycontin	Oxycodone Hcl	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Xifaxan	Rifaximin	12	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error